In this Episode

Dr. Jerry Rosenbaum

Until 2019 and for 20 years, Dr. Rosenbaum, Stanley Cobb Professor of Psychiatry at Harvard Medical School, chaired a department of 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as #1 in the United States in 2019, and for 20 of the prior 24 years, with 60 specialty clinical and research programs and over 70 million dollars of annual research spending. At MGH, the nation’s largest hospital based research institution, with over 1 billion dollars of annual research, he served as Chair of the Executive Committee on Research. The 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education, he was the 2016 recipient of the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty for Harvard Medical School. Emeritus Fellow of the ACNP, he is a 2018 Ellis Island Medal of Honor awardee. Past President/Board Chair of the Anxiety and Depression Association of America (ADAA), he served as Chair of the Scientific Council, President and Board member of the American Foundation for Suicide Prevention. He served a six year term as Trustee of the Massachusetts General Hospital, three years as Trustee of the Partners Healthcare System, and now co-Chair of Development at MGH. He is the co-author of more than 400 original articles and reviews, and editor of 20 books. He led longitudinal studies of children at risk for anxiety disorders and depression, examining behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders.

He currently is directing the MGH Center for Neuroscience of Psychedelics (CNP), to understand how psychedelics change the brain and to explore novel mechanisms for treatment of psychiatric disorders. He co-founded Psy Therapeutics to advance the discovery of novel drugs for psychiatric and neurologic disorders, co-founded Sensorium Therapeutics to explore plant derived molecules as leads for novel psychiatric therapeutics, and co-founded Entheos Labs, Inc. to bioengineer novel psychedelic botanicals to deliver a new generation of psychedelic-derived therapeutic molecules. He graduated in 1969 from Yale College and 1973 from Yale Medical School and trained in Psychiatry at Massachusetts General Hospital, Harvard Medical School.

Socials: Linkedin

Sharmin Ghaznavi, MD, Ph.D.

Sharmin Ghaznavi, MD, Ph.D., is the Associate Director and the Scientific Director of Cognitive Neuroscience at the Center for the Neuroscience of Psychedelics (CNP) at Massachusetts General Hospital. She is leading the Center’s first studies on the effects of psilocybin on rumination and other cognitive processes in major depression. Dr. Ghaznavi received her undergraduate degrees in biology, brain and cognitive sciences, and philosophy from the Massachusetts Institute of Technology. She obtained her medical degree, masters degree in philosophy, and Ph.D. in neuroscience from Yale University and completed a residency in adult psychiatry at the Mass General/McLean Psychiatry Residency Program. Dr. Ghaznavi’s research interests are the neural correlates of cognitive, affective and social processing in psychiatric illness. Dr. Ghaznavi has been the recipient of the Dupont-Warren and Livingston psychiatric research fellowships from Harvard Medical School and a 2012 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation.